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In this case series, we report for the first time a family in which the inherited nonsense 
mutation [c. 3946C > T (p.Arg1316*)] in the SCN5A gene segregates in association with 
Brugada syndrome (BrS). Moreover, we also report, for the first time, the frameshift 
mutation [c.7686delG (p.Ile2563fsX40)] in the NF1 gene, as well as its association with 
type 1 neurofibromatosis (NF1), characterized by pigmentary lesions (café au lait spots, 
Lisch nodules, freckling) and cutaneous neurofibromas. Both of these mutations and 
associated phenotypes were discovered in the same family. This genetic association 
may identify a subset of patients at higher risk of sudden cardiac death who require the 
appropriate electrophysiological evaluation. This case series highlights the importance 
of genetic testing not only to molecularly confirm the pathology but also to identify 
asymptomatic family members who need clinical examinations and preventive 
interventions, as well as to advise about the possibility of avoiding recurrence risk with 
medically assisted reproduction.
Keywords: Brugada syndrome, neurofibromatosis type 1, sudden cardiac death, genetic testing, mutation, 
arrhythmia, SCN5A, NF1
BACKGROUND
The Brugada syndrome (BrS) is an autosomal dominant condition with extreme clinical 
variability and incomplete penetrance (Nademanee et al., 2011; Lieve and Wilde, 2015; Monasky 
et  al., 2018). Brugada syndrome is characterized by a coved-type ST-segment elevation in 
the right precordial leads on the electrocardiogram (ECG) and by an increased risk of sudden 
cardiac death (SCD) (Antzelevitch et  al., 2016). Patients with a spontaneous type 1 BrS ECG 
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pattern are considered at higher risk for SCD, although patients 
can also be  diagnosed by administration of a sodium channel 
blocking agent, such as ajmaline (Antzelevitch et  al., 2016), 
which reveals the type 1 pattern. Patients can benefit from 
catheter ablation of the arrhythmogenic substrate (AS) located 
in the epicardial surface of the right ventricle (RV) (Nademanee 
et  al., 2011; Zhang et  al., 2015), preventing ventricular 
arrhythmias (VA) recurrences. The administration of ajmaline 
during the epicardial catheter ablation procedure helps to 
determine the exact location and full extent of the AS (Pappone 
et al., 2017). It is widely accepted that the majority of molecularly 
confirmed BrS cases result from a loss-of-function mutation 
in SCN5A, which encodes for a voltage-gated sodium channel 
subunit (Nav1.5). Heterozygous mutations in SCN5A are the 
most commonly diagnosed mutations associated with BrS 
(Di  Resta et  al., 2015; Sieira et  al., 2016; Curcio et  al., 2017) 
and account for 15–30% of BrS cases (Kapplinger et al., 2010). 
Nevertheless, a clear molecular confirmation is not achieved 
in most BrS cases, perhaps due to both locus heterogeneity 
and genomic imbalances undetectable by NGS methods 
(Sonoda  et  al., 2018).
Type 1 neurofibromatosis (NF1) is caused by heterozygous 
mutations in the NF1 gene (Gutmann et  al., 2017), and it is 
characterized by pigmentary lesions (café au lait spots, Lisch 
nodules, freckling) and cutaneous neurofibromas (Friedman, 
1993; Montani et al., 2011). Patients affected by NF1 can present 
with multiple organ involvement and hypertension, and they 
have a higher risk of developing malignant tumors than others 
of the same age in the general population (Friedman, 1993; 
Korf, 1999). The risk of developing gliomas (Friedman, 1993; 
Matsui et  al., 1993) and benign tumors (Matsui et  al., 1993; 
Anik and Abaci, 2014) is even higher than the risk of developing 
malignant ones, and in some cases, the benign tumors can 
become malignant (Miettinen et  al., 2017). At least half of 
patients with NF1 also present with learning disabilities 
(Friedman, 1993). Premature death in NF1 patients is frequently 
caused by cardiovascular disease, especially since severe 
complications of NF1 include vasculopathy, hypertension, and 
congenital heart defects (Friedman et  al., 2002).
In the present study, we  report for the first time a family 
in which the nonsense mutation [NM_198056.2:c. 3946C  >  T 
(p.Arg1316*)] in the SCN5A gene and the frameshift mutation 
[NM_001042492.2:c.7686delG (p.Ile2563fs*7)] in the NF1 gene 
segregate with the clinical phenotypes BrS and NF1, respectively.
CASE PRESENTATION
Proband (III-3)
Written informed consent of human subjects included in this 
case series report was obtained for their participation in the 
study and for publication of this case report. For patients 
under 18  years old, consent was obtained instead from the 
parents. The procedures employed were reviewed and approved 
by the Local Ethics Committee of San Raffaele Hospital, Milan, 
Italy. The proband is a 46-year-old male of Italian/Caucasian 
descent who presented with a family history characterized by 
a strong suspicion of NF1 on the maternal side of the family 
(Figure 1). In particular, his mother is affected by multiple 
cafè au lait spots, hyperthyroidism, and stomach malignant 
neoplasia (at 45 years old). His maternal grandmother had 
been affected by multiple cafè au lait spots and malignant gut 
neoplasm (age of onset unknown). A malignant gut neoplasm 
has been diagnosed recently also in the proband’s sister (50 
years old and without other clinical signs of NF1). No 
consanguinity in the family was reported.
The proband came to our attention for NF1 genetic counseling. 
This diagnosis was clinically confirmed based on international 
criteria (Gutmann et al., 1997). Indeed, our proband was affected 
by multiple cafè au lait spots, bilateral Lisch nodules, multiple 
benign skin neoplasms, bilateral axillary freckling, bilateral groin 
freckling, and a palpable lower left leg subcutaneous mass. 
We  advised the patient of the need for surgical removal of this 
mass. After a couple of months, the proband underwent surgical 
FIGURE 1 | Family pedigree. Proband identified with arrow. Triangle: Molecularly confirmed NF1 mutation; triangle with slash: genetic test for NF1 mutation 
performed but negative; star: molecularly confirmed SCN5A mutation; star with slash: genetic test for SCN5A mutation performed but negative; y.o.: years old 
at diagnosis.
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removal of four left lower limb masses, all histologically confirmed 
as “myxoid neurofibroma.” The preoperative ECG for this procedure 
revealed a type 2 BrS pattern. The patient then returned to us, 
and we recommended an electrophysiological evaluation. Therefore, 
the patient underwent an electrophysiological study (EPS), in 
which the patient tested negative for the inducibility of ventricular 
arrhythmias. However, the patient tested positive for BrS during 
a Flecainide test. One year after the first EPS, the proband 
repeated this procedure and was found to be  inducible, and an 
ICD was subsequently implanted. The patient then underwent 
successful epicardial ablation of the AS. The potential duration 
map, which shows the location and extent of the AS after 
ajmaline administration immediately before epicardial catheter 
ablation, can be  seen in Figure 2.
The patient underwent genetic testing for both BrS and 
NF1. Next-generation sequencing was used to analyze genomic 
DNA extracted from saliva. Results revealed a heterozygous 
nonsense mutation [c.3946C  >  T (p.Arg1316*)] in the SCN5A 
gene (LOVD genomic variant #0000406043, https://databases.
lovd.nl/shared/variants/0000406043) of unknown parental origin. 
Sanger sequencing was used to analyze genomic DNA extracted 
from peripheral blood. Results revealed a heterozygous frameshift 
mutation [c.7686delG (p.Ile2563fs*7)] in the NF1 gene (LOVD 
genomic variant #0000406041, https://databases.lovd.nl/shared/
variants/0000406041) of unknown parental origin (Figure 3).
Older Son (IV-9)
This 23-year-old male patient is the older son of the proband. 
He was clinically suspected for NF1, presenting with a family 
history of NF1 (affected father with molecular confirmation), 
multiple brain hamartoma (likely UBOs), multiple cafè au 
lait spots, and axillary and groin freckling. This clinical 
diagnosis was genetically confirmed with the finding of the 
same mutation in the NF1 gene found in his father. This 
patient was inducible during an EPS and diagnosed with BrS 
after a positive ajmaline test. An ICD was implanted the 
same day. The patient subsequently underwent successful 
epicardial catheter ablation of the AS. The potential duration 
map can be  seen in Figure 2. This patient was found to 
carry the same SCN5A mutation found in the proband from 
genomic DNA extracted from saliva.
Youngest Son (IV-10)
This 16-year-old male patient is the youngest son of the proband. 
He presented clinically with delayed speech (after the third year 
of life), delayed walking (after the fourth year of life), autism 
spectrum disorder, and one cafè au lait spot. He  was tested 
using genomic DNA extracted from peripheral blood for the 
NF1 mutation found in his father. However, he  tested negative 
for this mutation. Taking into consideration mood disturbances, 
the risk of self-aggressive behavior, and sleep disturbances, the 
patient was recommended to take valproic acid (750  +  500  mg/
day) and risperidone (1.5  mg 2x/day +1.25  mg/day). Due to 
this therapy, in addition to the family history, the patient 
performed a 12-lead ECG, which revealed a suspicious pattern 
suggestive of BrS. An ajmaline test confirmed the diagnosis of 
BrS. Ajmaline infusion resulted immediately in a type 1 pattern 
and required isoproterenol infusion to reverse a ventricular 
arrhythmia that had resulted in a compromise of the 
hemodynamics. An ICD was implanted the same day. In spite 
of the BrS diagnosis, the patient has not yet performed an 
ablation procedure. This patient underwent genetic testing for 
BrS from genomic DNA extracted from saliva and has been 
found to carry the same SCN5A mutation present in the proband.
Eldest Brother (III-1)
This 42-year-old male patient is the eldest brother of the 
proband. He  came to our attention with a suspicion of BrS 
based on both family history and recurrent syncope episodes. 
An ajmaline test confirmed the diagnosis of BrS, and an EPS 
was positive for induction of VA. The patient subsequently 
underwent an ICD implant. The skin examination revealed 
multiple cafè au lait spots, axillary freckling, and a few cutaneous 
nodules without histological examination to date. It has been 
clarified that these clinical elements (together with family 
history) are sufficient for the clinical diagnosis of NF1, according 
to international criteria (Gutmann et  al., 1997). An 
ophthalmological evaluation was recommended but has not 
yet been performed. The patient underwent successful epicardial 
catheter ablation of the AS. The potential duration map can 
be  seen in Figure 2. This patient was found to have both the 
NF1 and SCN5A mutations found in the proband from genomic 
DNA extracted from saliva.
Nephew (IV-1)
This 18-year-old male patient is the nephew of the proband 
and son of patient #III-1. At his clinical examination, multiple 
cafè au lait spots were detected. Taking into consideration the 
previous diagnosis of NF1  in this patient’s first- and second-
degree relatives (father and paternal uncle), NF1 was diagnosed 
in this patient as well, due to the clinically significant number 
of cafè au lait spots that totaled more than five and all with 
a diameter larger than 1.5  cm, according to the international 
criteria (Williams et al., 2009). It is noteworthy that this patient 
is also affected by learning disabilities, which is particularly 
more prevalent in NF1 patients compared with the general 
population (Torres Nupan et  al., 2017).
Based on family history, this patient underwent an EPS 
and ajmaline test, which were both positive for VA inducibility 
and for the type 1 pattern. For these reasons, he  received an 
ICD. The patient subsequently underwent successful epicardial 
catheter ablation of the AS. The potential duration map can 
be  seen in Figure 4. This patient was found to have both the 
NF1 and SCN5A mutations found in other family members 
from genomic DNA extracted from saliva.
Nephew (IV-2)
This 18-year-old male patient is the twin brother of patient 
#IV-1 and thus also the nephew of the proband and son of 
patient #III-1. At his clinical examination, he  showed multiple 
cafè au lait spots and axillary and groin freckling. Taking into 
consideration the previous diagnosis of NF1  in this patient’s 
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FIGURE 2 | Electrocardiograms and potential duration maps after ajmaline administration and immediately before epicardial catheter ablation. Patients: Proband, 
IV-9, and III-1.
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FIGURE 3 | Identification of the c. 3946C > T (p.Arg1316*) nonsense mutation in the SCN5A gene and the c.7686delG (p.Ile2563fs*7) frameshift mutation in the 
NF1 gene. (A,B) NGS paired-end reads loaded in the IGV genome browser. The arrow indicates the position of the single nucleotide variation in SCN5A gene (A) 
and of the deletion in NF1 gene (B) in patients (mut) compared to a wt control sample. SCN5A gene is in the reverse orientation on the chromosome. (C,D) Sanger 
sequencing electropherograms confirm the presence of the variants in SCN5A (C) and NF1 (D) in patients and their absence in the wt control. In the 
electropherogram of NF1 gene analysis, reverse strand is reported.
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first- and second-degree relatives, NF1 was diagnosed in this 
patient as well. Because of the family history, this patient also 
underwent an EPS and ajmaline test, which were positive for 
VA inducibility and the type 1 pattern. An ICD was then 
implanted. The patient subsequently underwent successful 
epicardial catheter ablation of the AS. The potential duration 
map can be seen in Figure 4. An echocardiogram demonstrated 
the presence of a Chiari network (Koz et  al., 2008) in the 
absence of other congenital heart defects. This patient was found 
to have both the NF1 and SCN5A mutations found in other 
family members from genomic DNA extracted from saliva.
Niece (IV-3)
This 8-year-old female was diagnosed with NF1 due to the 
presence of multiple cafè au lait spots and Lisch nodules, as 
well as the family history. Due to her age, she has never been 
tested for BrS to date, but the 12-lead ECG demonstrated a 
spontaneous normal pattern. This patient is asymptomatic to 
date, and she was found to be  positive for the familiar NF1 
mutation but negative for the familiar SCN5A mutation as 
analyzed from genomic DNA extracted from saliva.
Nephew (IV-11)
This 31-year-old male patient is another nephew of the proband. 
While his father (the proband’s brother, III-5) is clinically affected 
by NF1 and BrS, patient IV-11 did not show any signs of NF1 
when clinically examined, and he  tested negative for BrS in 
an ajmaline challenge. This patient was found to be  negative 
for both the NF1 and SCN5A mutations found in other family 
members from genomic DNA extracted from saliva.
FIGURE 4 | Electrocardiograms and potential duration maps after ajmaline administration and immediately before epicardial catheter ablation. Patients IV-1 and IV-2.
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DISCUSSION
In this case series, we  report for the first time a family in 
which the inherited nonsense mutation [c. 3946C  >  T 
(p.Arg1316*)] in the SCN5A gene segregates in association with 
BrS. Moreover, we  also report, for the first time, the familial 
segregation of the novel frameshift mutation [c.7686delG 
(p.Ile2563fsX40)] in the NF1 gene and the association of this 
mutation with NF1. Furthermore, to the best of our knowledge, 
it is the first time that any family has been reported to have 
both BrS and NF1. Neurofibromin plays an essential role in 
cardiac development. Patients with NF1 mutations exhibit several 
vascular abnormalities, such as aneurysms or stenosis of the 
aortic, renal, and mesenteric arteries (Oderich et  al., 2007). 
Tedesco and colleagues reported a higher incidence of heart 
abnormalities diagnosed by ultrasound in unrelated NF1 patients 
in sinus rhythm compared to controls (Tedesco et  al., 2002). 
Recently, Incecik and colleagues described a higher incidence 
of cardiac abnormalities in NF1 pediatric patients, with potentially 
poor prognoses (Incecik et  al., 2015).
NF1 patients present with extreme clinical variability, including 
even between members of the same family. The majority of NF1 
patients with vascular damage are asymptomatic, which can make 
diagnosis a challenge (Rerat et  al., 2015). As a consequence, 
NF1 vasculopathy is often identified only after autopsy (Hamilton 
et  al., 2001). In cases in which NF1 leads to sudden death, the 
fatalities usually occur in adulthood and are usually attributed 
to a central nervous system tumor (Koszyca et al., 1993). However, 
there are also reports of sudden cardiac death in young children 
with NF1. Kanter and colleagues described two cases of unrelated 
children clinically affected by NF1 and by a coronary artery 
occlusion, causing ventricular fibrillation and sudden death (Kanter 
et  al., 2006). One clinical study investigating the relationship 
between NF1 and arrhythmias reported fewer cases of bradycardia 
in the NF1 patient population, suggesting the involvement of 
the vagus nerve (Malmcrona et  al., 1996).
Neurofibromin plays a pivotal role in molecular and 
cellular pathways, particularly with an inhibitory action on 
Ras proteins (Upadhyaya, 2010) that are potent factors in 
triggering cell growth and signaling (Rose et  al., 2018). 
Neurofibromin exists in at least four alternative primary 
structures. The expression of isoforms 3 and 4 has been 
discovered in cardiac muscle in rodents (Gutmann et  al., 
1995). In animal models, neurofibromin is critical for heart 
development and prevents vascular diseases through Ras 
downregulation that regulates the development of endocardial 
cushions, ventricular growth, and fibrosis (Lakkis and Epstein, 
1998; Xu et  al., 2009). The abolishment of myocardial 
neurofibromin expression in a knockout mouse model 
suggested that neurofibromin loss activates the Ras pathway, 
resulting in progressive cardiac hypertrophy, fibrosis, and 
cardiac myocyte enlargement (Xu et  al., 2009).
It has been widely demonstrated that the protein Nav1.5 
encoded by the SCN5A gene is an essential controller of cardiac 
excitability, and recent studies underlined that loss of function 
mutations in SCN5A is associated with increased cardiac 
dimensions and reduced contractility (van Hoorn et  al., 2012). 
Another study by Tedesco and colleagues highlighted that also 
NF1 patients even without arterial hypertension can show 
alterations in Doppler tissue imaging (Tedesco et  al., 2005). 
Understanding the clinical significance of individual SCN5A 
mutations is challenging, given the extreme clinical variability 
seen in patients with SCN5A mutations (Kyndt et  al., 2001; 
Six et  al., 2008), the variability in the types of mutations and 
locations within the gene, the number of mutations, genetic 
heterogeneity, and the fact that some of these variants are 
found in the general population (Juang et al., 2015). Regardless, 
nonsense heterozygous mutations in the SCN5A gene are 
generally accepted as causative of BrS (Samani et  al., 2009; 
Gando et  al., 2017).
In the present report, two spontaneous abortions occurred 
in a row, both in the first trimester. Recent literature suggests 
a genetic study on abortive product after the second consecutive 
pregnancy loss in the presence of other certain factors that 
occur at a higher prevalence than 1/100 women (Hyde and 
Schust, 2015). In such cases, testing for balanced translocation 
of the chromosomes may be  considered (Hyde and Schust, 
2015). However, in the present report, the cause of the abortions 
is unknown.
These data may highlight a close relationship between 
neurofibromatosis and BrS, because all the members genetically 
affected were also inducible for VAs during the EPS, which 
suggests a subset of patients with an aggressive BrS phenotype. 
Therefore, this may suggest that when neurofibromatosis and 
BrS are suspected, an extremely careful evaluation of these 
patients should be  performed, as the phenotype manifestation 
of the combination of these diseases could be  life-threatening. 
Further studies are warranted to investigate these findings in 
a larger subset of patients.
Taken together these data show how genetic counseling can 
be  useful for a family. The molecular confirmation in 
asymptomatic members can prompt a clinical examination and 
preventive interventions. Additionally, affected individuals can 
be  advised about the possibility of avoiding recurrence risk 
with medically assisted reproduction.
CONCLUDING REMARKS
This study is the first family in which the nonsense mutation 
[NM_198056.2:c. 3946C > T (p.Arg1316*)] in the SCN5A gene 
and the frameshift mutation [NM_001042492.2:c.7686delG 
(p.Ile2563fs*7)] in the NF1 gene segregate with the clinical 
phenotypes BrS and NF1, respectively. NF1 patients should 
be  routinely checked for cardiac and vascular abnormalities. 
The co-expression of NF1 and BrS may result in a subset of 
patients at higher risk of SCD who require the appropriate 
electrophysiological evaluation. The importance of genetic testing 
should be emphasized to identify family members who require 
clinical examinations and preventive interventions, as well as 
to advise about the possibility of avoiding recurrence risk with 
medically assisted reproduction.
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